Microbial contamination of hematopoietic progenitor cell products: clinical outcome.
We reviewed the results of routine microbiological assays of 3078 infused hematopoietic progenitor cell (HPC) products for autologous and allogeneic transplantation between January 2001 and December 2005. Thirty-seven (1.2%) contaminated products were found. All patients receiving contaminated infusions received empirical antibiotic prophylaxis according to the assay result. None of these patients developed a positive blood culture with the same agent, developed infections that could be attributable to the contaminated product or experienced any clinical sequelae. Coagulase-negative Staphylococcus was found in 32 (86.5%) products. Admission lengths and time to engraftment were within the expected time frame for autologous and allogeneic transplants. Microbial contamination of HPC products occurs at a low frequency; prophylactic use of antibiotics based on the microbiological assay appears to be effective in preventing clinical complications.
Patah
P A
PA
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77035, USA.
Parmar
S
S
McMannis
J
J
Sadeghi
T
T
Karandish
S
S
Rondon
G
G
Tarrand
J
J
Champlin
R
R
de Lima
M
M
Shpall
E J
EJ
D019072:Antibiotic Prophylaxis / Q000379:methods; D016470:Bacteremia / Q000517:prevention & control; D001781:Blood Component Removal / Q000379:methods; D003428:Cross Infection / Q000382:microbiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006412:Hematopoietic Stem Cells / Q000382:microbiology*; D006801:Humans; D008485:Medical Audit; D012189:Retrospective Studies; D013781:Texas; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous